



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.

Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Dear Sir,

We are here with enclosing a copy of Press Release issued by the Company for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

T. Chaitanya


**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**

Encl as above



Press Release

Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd., launched generic Methylergonovine tablets in partnership with Hikma.

Hyderabad India – May 30th 2018. Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd., has launched the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine in partnership with West-Ward Pharmaceuticals Corp. (West-Ward), a wholly-owned subsidiary of Hikma Pharmaceuticals PLC (Hikma).

Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage.

“This is the first product we have commercialized from our R&D and manufacturing facility in Virginia and we are happy to have collaborated with Hikma . Apart from the fact that Hikma has a proven history of being a responsible player in the market, we look at this launch as the inception towards building a strategic relationship. The launch of generic Methergine tablets plays into our strategy of identifying patient needs and catering to them with economical alternatives.” said Ms. Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals, Inc.

Brian Hoffmann, President of West-Ward, said, “We are very pleased to be entering into a partnership with Granules Pharmaceuticals, Inc., adding this important oxytocic agent to our product portfolio in the US. This partnership demonstrates our focus on improving patient’s access to high-quality, affordable medicines.”



About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules India support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K.

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

Contacts:

Sumanta Bajpayee
Corporate Finance & Investor Relations
040-30663572
sumanta.bajpayee@granulesindia.com

Chaitanya Tummala
Company Secretary
040-30663614
chaitanya.tummala@granulesindia.com

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs, and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.